期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

反应停治疗浆细胞肿瘤的临床研究 被引量：4

下载PDF
导出
摘要 目的　观察反应停 (thaldomide)治疗难治性浆细胞肿瘤的有效性和毒性。方法　 10例浆细胞肿瘤患者 ,反应停 2 0 0～ 40 0mg每晚 1次至少服用 1个月。 结果　部分缓解 (PR) 3例 ,进步 3例 ,无效 4例 ;副作用可耐受 ,便秘最常见 (7/ 10 )。结论　每日 30 0～ 40
作者 吴德沛 唐晓文 孙爱宁 傅铮铮 苗瞄 李建勇 夏学鸣 林宝爵
机构地区 苏州大学附属第一医院血液科
出处 《江苏医药》 CAS CSCD 北大核心 2001年第2期131-132,共2页 Jiangsu Medical Journal
关键词 反应停 浆细胞肿瘤 多发性骨髓瘤 治疗
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1[1]Singhal S，Mehta J，Desikan R，et al．Anti-tumor activity of thalidomide in refractory multiple myeloma．N Eng J Med，1999，341:1565-1571．
  • 2[2]Parman T，Wiley MJ，Wells PG，et al．Free radial-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity．Nature Medicine，1999，5:582-585．
  • 3[3]Geitz H，Handt S，Zwingenger K，Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade．Immunopharmacology，1996，32:213-221．
  • 4[4]Corral LG，Haslett PAJ，Muller GW，et al．Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α． J Immunol，1999，163:380-386．
  • 5[5]Vacca A，Ribatti D，Presta M，et al．Bone marrow neovascularization，plasma cell angiogenic potential，and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma．Blood，1999，13:3064-3073．
  • 6[6]Bellamy W，Richter L，Frutigar Y，et al．Expression of vasular endothelial growth factor and its receptor in hematological malignancies．Cancer Res，1999，59:728-733．
  • 7[7]Haslett PAJ，Corral LG，Albert M，et al．Thalidomide costimulates primary human T lymphocytes，preferentially inducing proliferation，cytokine production，and cytotoxic responses in the CD8＋ subset．J Exp Med，1998，187:1885-1892．
  • 8[8]Juliusson G，Celsing F，Turesson Ι，et al．Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma．Br J Haematol，2000，109:89-96．
  • 9[9]Kneller A，Raanani P，Hardan I，et al．Therapy with thalidomide in refractory multiple myeloma-the revival of an old drug．Br J Haematol 2000；108:391-393．

同被引文献15

  • 1Olson KB, Hall TC, Horton J, et al. Thalidomide (N-phthaloylgln tamimide) in the treatment of advanced cancer[J]. Clin Pharmacol Ther, 1965, 6: 292.
  • 2Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med,1999, 341: 1565.
  • 3Barlogie B, Desikan R, Eddlemon P, et aL Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients[J]. Blood, 2001,98: 492.
  • 4Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicityin multiple myeloma[J]. Blood, 2001, 98: 210.
  • 5Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J]. Blood, 2000, 96: 293.
  • 6Kneller A, Paanani I, Hardan A, et al. Therapy with thalidomide in refractory mutiplae myeloma patients-the revival of an old drug. Br J Haematol.2000,108: 391-393.
  • 7Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single -agent thalidomide: identification of prognosfic factors in a phase 2 study of 169patients. Blood, 2001,98 (2): 492 ～ 494.
  • 8Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood,2001,98(1) :210 ～216.
  • 9Peuckmann V, fisch M, Bruera E. Potential novel of thalidomide: focus on palliative care. Drugs, 2000,60 (2): 273 ～ 292.
  • 10Larkin M. Low - dose thalidomide seems to be effective in multiple myeloma. Lancet, 1999, 354(9182): 925 - 927.

引证文献4

二级引证文献15

江苏医药
2001年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部